IMV

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, today announced that data from a clinical study of
DPX-Survivac, a therapeutic cancer vaccine, will be presented in the
Developmental Therapeutics - Immunotherapy poster session at the American
Society of Clinical Oncology (ASCO) 2013 Annual Meeting. The ASCO Annual Meeting
will be held May 31 - June 4, 2013, in Chicago. 


The poster presentation will highlight data from Immunovaccine's Phase I
clinical trial of DPX-Survivac in patients with ovarian cancer. This trial
tested the combination of DPX-Survivac with low dose oral cyclophosphamide.
Findings discussed will focus on the safety and immune potential of DPX-Survivac
and the effect of cyclophosphamide on vaccine-induced survivin-specific T cell
responses.


Details of the poster presentation are as follows:



Abstract #3030:  Effect of oral cyclophosphamide on the immunogenicity of   
                 DPX-Survivac in ovarian cancer patients: Results of a Phase
                 I study.                                                   
                                                                            
                 Marc Mansour, Ph.D; Immunovaccine's Chief Science Officer  
                 Poster Board #22                                           
                 Saturday, June 1, 2013, 1:15 - 5:15 p.m.                   
                 Location: S405                                             



Details of the poster discussion session that will follow:



                 Saturday, June 1, 2013, 5:30 - 5:45 p.m.                   
                 Location: S406                                             



About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in multiple cancer types in addition to ovarian cancer, including
breast, colon and lung cancers. Survivin plays an essential role in antagonizing
apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to
various anti-cancer therapies. Survivin is also a prognostic factor for many
cancers and it is found in a higher percentage of tumors than other TAA's.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to search
actively and specifically for tumor cells and destroy them. Survivin-specific
T-cells have been shown to target and kill survivin-expressing cancer cells
while sparing normal cells.


About DepoVax

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024